Drug intelligence / Profile preview

dexamethasone + metoclopramide + ondansetron

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous, Sublingual

Overview

A combination antiemetic regimen consisting of dexamethasone (a corticosteroid), metoclopramide (a dopamine antagonist), and ondansetron (a serotonin/5-HT3 receptor antagonist). This triple therapy leverages different mechanisms of action to provide comprehensive control of nausea and vomiting. Dexamethasone enhances the antiemetic effect of other agents, metoclopramide blocks the vomiting center and promotes gastric emptying, while ondansetron blocks serotonin receptors in the gut and brain that trigger nausea and vomiting.

Targets

DRD2 (Dopamine D2 Receptor)HTR4 (5-Hydroxytryptamine receptor 4)HTR3A (5-hydroxytryptamine receptor 3A)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + metoclopramide + ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + metoclopramide + ondansetron.

Explore the full profile